Royalty Report: Drugs, Pharmaceuticals, Biotechnology – Collection: 5579


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5579

License Grant
The Company also received a non-exclusive license to develop, market, and sell certain products incorporating Licensor’s compounds Moli56A and Moli56B with respect to the products to be used in the field of treating septic shock in non-human mammals,containing the iron containing compounds Moli56A (commonly known as DTPA iron (III)) and Moli56B (commonly known as Ferrioxamine B).
Field of Use
Field of use shall mean use of the technology in the  treatment of septic shock in non-human mammals.

IPSCIO Record ID: 5535

License Grant
On May 6, 2003, related party transaction where a non-exclusive license to develop, market, and sell certain products incorporating compounds Moli56A and Moli56B was granted. Moli56A and Moli56B (treatment of sepsis) are in the pre-clinical trials stage of development.

IPSCIO Record ID: 26739

License Grant
Under a research agreement with the University, the Licensee funded T(beta)4 research for the Licensor and was granted a sole and exclusive world-wide license to any patents that resulted from such research.
License Property
T(beta)4 is used for the treatment of septic shock and associated syndromes, including ARDS.

Two U.S. patents have issued.  The first patent, No.  5,578,570, entitled Method of Treating Septic Shock Using T(beta)4 and the second patent, No. 5,593,964, entitled Method of Treating Septic Shock By Preventing Actin Polymerization.  The Company’s current primary business focus is the commercialization of Thymosin beta 4, a 43 amino acid peptide (T(beta)4).

Field of Use
The Licensee is concentrating its efforts on the use of T(beta)4 for the treatment of injured tissue and non-healing wounds to enable more rapid repair and/or tissue regeneration.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.